Europeiska unionen - maltesiska - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psorajiżi - immunosoppressanti - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

shionogi b.v. - naldemedine tosilate - stitikezza - mediċini għall-istitikezza, periferali opioid ta ' l-antagonisti tar-riċettur - rizmoic huwa indikat għat-trattament ta ' stitikezza ikkaġunata minħabba opjojdi (oic) fil-pazjenti adulti li jkunu diġà ġew ittrattati bl-lassattiv.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressanti - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol acetate, mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - ażma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Europeiska unionen - maltesiska - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.